Pharmaceutical

Takeda’s ADZYNMA gains EU approval for cTTP treatment

The European Commission (EC) has approved Takeda's ADZYNMA (recombinant ADAMTS13) for congenital thrombotic thrombocytopenic purpura (cTTP).

Aug 9, 2024 - 04:00
Takeda’s ADZYNMA gains EU approval for cTTP treatment
The European Commission (EC) has approved Takeda's ADZYNMA (recombinant ADAMTS13) for congenital thrombotic thrombocytopenic purpura (cTTP).
Read the original article

Tags:

Previous Article

Bavarian Nordic tops up US smallpox/mpox vaccine stockpile with $156.8m order

Next Article

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Phase I completion of Sanofi’s vWD therapy demonstrates promise of pipeline

Phase I completion of Sanofi’s vWD therapy demonstrates...

May 16, 2023

A new deal aims to ramp up use of AI in rehab care decisions

A new deal aims to ramp up use of AI in rehab care deci...

Jul 20, 2023

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

FDA moves to stop vape shops from selling Elf Bar, Esco...

Jun 22, 2023